A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Hani Hassoun, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tufts Medical Center (data Collection Only)
Boston, Massachusetts, United States
Active, not recruiting - Memorial Sloan Kettering Basking Ridge (limited Protocol Activities)
Basking Ridge, New Jersey, United States
Recruiting - Memorial Sloan Kettering Monmouth (limited Protocol Activities)
Middletown, New Jersey, United States
Recruiting - Memorial Sloan Kettering Bergen (limited Protocol Activities)
Montvale, New Jersey, United States
Recruiting - Memorial Sloan Kettering Cancer Center Suffolk - Commack (limited Protocol Activities)
Commack, New York, United States
Recruiting - Memorial Sloan Kettering Westchester (limited Protocol Activities)
Harrison, New York, United States
Recruiting - Memorial Sloan Kettering Cancer Center (all Protocol Activities)
New York, New York, United States
Recruiting - Mount Sinai Hospital (data Collection Only)
New York, New York, United States
Completed - Weill Cornell Medical Center (data Collection Only)
New York, New York, United States
Not, yet, recruiting - Memorial Sloan Kettering Nassau (limited Protocol Activities)
Uniondale, New York, United States
Recruiting - University of North Carolina (data Collection Only)
Chapel Hill, North Carolina, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Oct 2023
- Primary completion
- 31 Oct 2026
- Completion
- 31 Oct 2026
- Last update posted
- 6 Jul 2026
- Registered enrollment
- 20
- Registry id
- NCT06083922
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.